Andrea Mammoli

Dr. Andrea Mammoli

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
JDJenny Desantis
Jenny Desantis
AMAndrea Mammoli
Andrea Mammoli
MEMichela Eleuteri
Michela Eleuteri
ACAlice Coletti
Alice Coletti
FCFederico Croci
Federico Croci
LGLaura Goracci
Laura Goracci
The pKa values of a dataset of PROTACs and PROTAC precursors have been analyzed in order to show how a fine modulation of piperazine-containing linkers can impact their protonation state.

1 December 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
GMGiada Mondanelli
Giada Mondanelli
VBValeria Di Battista
Valeria Di Battista
FPFabrizia Pellanera
Fabrizia Pellanera
AMAndrea Mammoli
Andrea Mammoli
AMAntonio Macchiarulo
Antonio Macchiarulo
CMCristina Mecucci
Cristina Mecucci

19 March 2020 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
AMAndrea Mammoli
Andrea Mammoli
ACAlice Coletti
Alice Coletti
MBMarco Ballarotto
Marco Ballarotto
ARAlessandra Riccio
Alessandra Riccio
ACAndrea Carotti
Andrea Carotti
Antonio MacchiaruloAntonio Macchiarulo
Antonio Macchiarulo

1 November 2020 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MFMartina Ferri
Martina Ferri
MAManuel Alunno
Manuel Alunno
FGFrancesco Antonio Greco
Francesco Antonio Greco
AMAndrea Mammoli
Andrea Mammoli
GSGiorgio Saluti
Giorgio Saluti
PLParide Liscio
Paride Liscio

Verified
Journal Article
Open access
PDF file
AMAndrea Mammoli
Andrea Mammoli
EBElisa Bianconi
Elisa Bianconi
LRLuana Ruta
Luana Ruta
ARAlessandra Riccio
Alessandra Riccio
Carlo BigiottiCarlo Bigiotti
Carlo Bigiotti
Antonio MacchiaruloAntonio Macchiarulo
Antonio Macchiarulo
Over the last two decades, indoleamine 2,3-dioxygenase 1 (IDO1) has attracted wide interest as a key player in immune regulation, fostering the design and development of small molecule inhibitors to restore immune response in tumor immunity. In this framework, biochemical, structural, and pharmacological studies have unveiled peculiar structural plasticity of IDO1, with different conformations and functional states that are coupled to fine regulation of its catalytic activity and non-enzymic functions. The large plasticity of IDO1 may affect its ligand recognition process, generating bias in structure-based drug design campaigns. In this work, we report a screening campaign of a fragment library of compounds, grounding on the use of three distinct conformations of IDO1 that recapitulate its structural plasticity to some extent. Results are instrumental to discuss tips and pitfalls that, due to the large plasticity of the enzyme, may influence the identification of novel and differentiated chemical scaffolds of IDO1 ligands in structure-based screening campaigns.